Litcius/Paper detail

CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent

Jingzhe Wang, Bakhos A. Tannous, Mark C. Poznansky, Huabiao Chen

2020Pharmacological Research131 citationsDOI

Topics & Concepts

PlerixaforCXCR4 antagonistCXCR4MedicineCancer researchHaematopoiesisTumor microenvironmentLymphomaImmunologyImmune systemPharmacologyStem cellBiologyChemokineCell biologyChemokine receptors and signalingImmunotherapy and Immune ResponsesImmune Cell Function and Interaction
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent | Litcius